CDKN2A and astrocytoma (excluding glioblastoma): Recent investigations found a significantly shorter survival among patients with IDHmt astrocytomas (all grades included) with hemizygous deletion of CDKN2A/B on multivariate analysis in independent datasets, with an intermediate overall survival of patients with hemizygous deletion of CDKN2A/B compared to patients with CDKN2A/B homozygously deleted tumors and patients whose tumors lacked copy number losses of CDKN2A/B.